Is KAZIA THERAPEUTICS LTD (KZIA) Halal?
Shariah Screening — 5 Standards
Based on financial data from June 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.4% / 30% | 4.6% / 30% | 0.1% / 30% | 171.43% / 5% | ✗ NOT HALAL |
| DJIM | 0.4% / 33% | 4.6% / 33% | 0.1% / 33% | 171.43% / 5% | ✗ NOT HALAL |
| MSCI | 6.5% / 33% | 71.7% / 33% | 1.5% / 33% | 171.43% / 5% | ✗ NOT HALAL |
| S&P | 0.4% / 33% | 4.6% / 33% | 0.1% / 33% | 171.43% / 5% | ✗ NOT HALAL |
| FTSE | 6.5% / 33% | 71.7% / 33% | 1.5% / 50% | 171.43% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -14641.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -106.9% | |
| Return on Assets (ROA) | -25.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$13M |
| Free Cash Flow | -$13M |
| Total Debt | $396,000 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 2.9 |
| Total Assets | $6M |
Price & Trading
| Last Close | $7.26 |
| 50-Day MA | $7.06 |
| 200-Day MA | $7.95 |
| Avg Volume | 214K |
| Beta | 1.6 |
|
52-Week Range
$2.86
| |
About KAZIA THERAPEUTICS LTD (KZIA)
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is KAZIA THERAPEUTICS LTD (KZIA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), KAZIA THERAPEUTICS LTD is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is KAZIA THERAPEUTICS LTD's debt ratio?
KAZIA THERAPEUTICS LTD's debt ratio is 0.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.5%.
What are KAZIA THERAPEUTICS LTD's key financial metrics?
KAZIA THERAPEUTICS LTD has a market capitalization of $82M, and revenue of $42,000. Return on equity stands at -106.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.